RECOVERY OF PLATELET FUNCTION FOLLOWING DISCONTINUATION OF PRASUGREL OR CLOPIDOGREL MAINTENANCE DOSING IN ASPIRIN-TREATED SUBJECTS WITH STABLE CORONARY DISEASE: THE RECOVERY TRIAL

Matthew J. Price(Scripps Clinic), Dominick J. Angiolillo(University of Florida), Darell Heiselman(Eli Lilly (United States)), Brian Baker, Wei Li, Kenneth J. Winters(Eli Lilly (United States)), James Walder(University of North Carolina at Chapel Hill), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Douglas Logan(Medpace (United States))
Journal of the American College of Cardiology
April 1, 2011
10.1016/s0735-1097(11)61636-7
Cited by 5

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
|New England Journal of Medicine|2009|618